Clinical Trial

IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 29, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3014 in participants with unresectable locally advanced or metastatic solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-13.
Trial Details
NCT Number NCT06974812
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Unresectable Locally Advanced or Metastatic Solid Tumors
Enrollment 250 participants
Start Date 2025-04-18
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-29